EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly

A Giustina; P Chanson; D Kleinberg; MD Bronstein; DR Clemmons; A Klibanski; AJ (Aart-Jan) van der Lely; CJ Strasburger; S.W.J. Lamberts; KKY Ho; FF Casanueva; S Melmed

doi:10.1038/nrendo.2014.21

EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly

A Giustina, P Chanson, D Kleinberg, MD Bronstein, DR Clemmons, A Klibanski, AJ (Aart-Jan) van der Lely, CJ Strasburger, S.W.J. Lamberts, KKY Ho, FF Casanueva, S Melmed

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

319 Citations (Scopus)

Abstract

In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.

Original language	Undefined/Unknown
Pages (from-to)	243-248
Number of pages	6
Journal	Nature Reviews Endocrinology
Volume	10
Issue number	4
DOIs	https://doi.org/10.1038/nrendo.2014.21
Publication status	Published - 2014

Research programs

EMC MM-01-39-01
EMC MM-01-39-04

Access to Document

10.1038/nrendo.2014.21

http://hdl.handle.net/1765/58875

Cite this

@article{41b560a546ed490ca36b2e17e8e60671,

title = "EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly",

abstract = "In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.",

author = "A Giustina and P Chanson and D Kleinberg and MD Bronstein and DR Clemmons and A Klibanski and {van der Lely}, {AJ (Aart-Jan)} and CJ Strasburger and S.W.J. Lamberts and KKY Ho and FF Casanueva and S Melmed",

year = "2014",

doi = "10.1038/nrendo.2014.21",

language = "Undefined/Unknown",

volume = "10",

pages = "243--248",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly

AU - Giustina, A

AU - Chanson, P

AU - Kleinberg, D

AU - Bronstein, MD

AU - Clemmons, DR

AU - Klibanski, A

AU - van der Lely, AJ (Aart-Jan)

AU - Strasburger, CJ

AU - Lamberts, S.W.J.

AU - Ho, KKY

AU - Casanueva, FF

AU - Melmed, S

PY - 2014

Y1 - 2014

N2 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.

AB - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.

U2 - 10.1038/nrendo.2014.21

DO - 10.1038/nrendo.2014.21

M3 - Article

C2 - 24566817

SN - 1759-5029

VL - 10

SP - 243

EP - 248

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

IS - 4

ER -